In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae

Size: px
Start display at page:

Download "In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae"

Transcription

1 AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi: /aac Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae Kevin Pettus 1, Samera Sharpe 1, John Papp Centers for Disease Control and Prevention, Atlanta, Georgia 5 6 Running Head: Antibiotic therapy for N. gonorrhoeae infection Address correspondence to John R Papp. jwp6@cdc.gov. John R Papp, PhD Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, Mail Stop A-12, Atlanta, GA Phone: Fax: All authors contributed equally to this work. 19 1

2 20 Abstract Development of resistance to first line antimicrobial therapies has led to the recommendation to use combination therapies for gonorrhea. Recent studies have shown success of combination therapy in treating patients but few report in vitro activity of drug combinations. The in vitro assessment of azithromycin in combination with gentamicin demonstrated inhibition of growth and suggests that clinical trials of effectiveness may be warranted to assess their utility in treating gonorrhea infections. 26 2

3 Clinical management of Neisseria gonorrhoeae, a common sexually transmitted bacterial pathogen, is complicated by the ability of the organism to become resistant to antibiotics through genetic mutations and/or acquisition of resistance conferring genes (1). Antimicrobial resistance in N. gonorrhoeae occurs as chromosomally mediated resistance to a variety of antimicrobial agents, including penicillin, tetracycline, spectinomycin, and fluoroquinolones, and high-level, plasmid-mediated resistance to penicillin and tetracycline (2). The Centers for Disease Control and Prevention (CDC) currently recommends that uncomplicated gonococcal infections be treated with ceftriaxone in combination with azithromycin or doxycycline (3). Combination therapy is hypothesized to lessen survivability of N. gonorrhoeae strain that becomes resistant to one or the other antibiotic. The combination of ceftriaxone or cefixime plus azithromycin was shown to effectively inhibit N. gonorrhoeae growth in vitro through independent actions (4). However, the effect of drug combinations involving azithromycin on N. gonorrhoeae growth has not been well studied In vitro drug activity against N. gonorrhoeae can be determined by either diffusion or dilution methods. The agar plate dilution method is considered to be the standard reference method and is used in the CDC s Gonocococcal Isolate Surveillance Project (5) which monitors susceptibility trends in the US to inform treatment recommendations. The method is most appropriate to assess drug combinations since the dilutions are incorporated directly into the agar and not prone to differences in diffusion if disk or strip tests are used. In the present study, combinations azithromycin/gentamicin, azithromycin/rifampicin and azithromycin/ciprofloxacin were tested against a panel of clinical N. gonorrhoeae isolates to determine if there was any synergistic or antagonist effect on bacterial growth A total of 99 N. gonorrhoeae clinical isolates, collected as part of the Gonoococcal Isolate Surveillance Project from2005 to 2007 from STD clinics across the US (5), were selected based on having a range of susceptibility to azithromycin and ciprofloxacin. Isolates were stored frozen at -70 o C in tryptic soy broth containing 20% glycerol from time of initial testing. Stock solutions of azithromycin (Sigma-Aldrich), gentamicin (Sigma-Aldrich), rifampicin (Sigma-Aldrich) and ciprofloxacin (Sigma-Aldrich) were prepared and serial dilutions 3

4 incorporated into GC II agar base medium (Difco) supplemented with 1% IsoVitaleX (Fisher) maintained at 50 o C. The final concentration of azithromycin was 0 to 8.0 g/ml in combination with 0 to 32 g/ml of gentamicin. A similar range of azithromycin dilutions was used in combination with 0 to 64 g/ml of ciprofloxacin and 0 to 8 g/ml of rifampicin. Following the addition of antibiotic dilutions, the medium was poured into square 100mm x 100mm Petri dishes. The medium was allowed to solidify and the plates were stored at 4 o C for up to one month prior to use. An overnight growth of an isolate on chocolate agar was suspended in Mueller-Hinton broth (Becton Dickinson) to a concentration of 10 8 colony forming units. The bacterial suspensions were inoculated onto the antibiotic containing agar plates using a Steers replicator that allows for up to 36 isolates to be tested on one plate. The minimum inhibitory concentration (MIC; all isolates inhibited), MIC 50 (50% of isolates inhibited) and MIC 90 (90% of isolates inhibited) of single and drug combination was determined after 20 to 24 hours incubation at 36.5 o C under 5% CO 2. For analysis, results were arbitrarily stratified by MIC values into low, medium and elevated groupings to assess differences between these values. There were no medium rifampicin MIC values for isolate grouping. A fractional inhibitory index (FICI) was calculated as previously described (4, 6). The FICI was used to assess synergy (FICI 0.5), indifference (FICI ) or antagonism (FICI >4.0) of the antibiotic combinations. The accuracy of the antibiotic dilutions was assessed using N. gonorrhoeae quality control strains F18, F28, P681E, 10328, 10329, SPJ-15, and SPL-4. Only results from quality control validated test runs that had expected MIC values for azithromycin, gentamicin, rifampicin and ciprofloxacin were used in the analysis The MIC 50 and MIC 90 of antibiotic combinations on the growth of N. gonorrhoeae were compared to values from single antibiotic dilutions (Table 1). There was slight one dilution decrease of the MIC 50 and MIC 90 of azithromycin when used in combination with gentamicin. Azithromycin plus ciprofloxacin resulted in a one dilution decrease for the MIC 90 but not MIC 50 of ciprofloxacin. There was no effect on the azithromycin MIC values in combination with ciprofloxacin. In contrast, the MIC 50 of rifampicin increased by two dilutions when azithromycin was added. However, the MIC 90 of rifampicin and azithromycin was the same as those from plates 75 with one antibiotic. There were slight differences in the reproducibility of single MIC values for azithromycin 4

5 when tested for each antibiotic combination but these values did not differ by more than one dilution. This was primarily noted when testing the combination of azithromycin and ciprofloxacin when the single MIC values for some isolates altered the number of isolates within the arbitrary groupings There was no antibiotic synergy or antagonism when azithromycin was paired with either gentamicin or ciprofloxacin (Tables 2 and 3). Though the overall FICI interpretation of rifampicin and azithromycin was indifference (Table 4), antagonism was observed with 23 isolates. The azithromycin and rifampicin MIC values for these 23 isolates ranged from to 8µg/ml and to 8µg/ml, respectively. There was no stratification by single drug MIC values for those isolates in which antagonism was noted between rifampicin and azithromycin. Comparing the genomic sequences of isolates that had drug antagonism to those without may elucidate the mechanisms responsible for these observations. These in vitro data suggest that rifampicin should not be considered in combination with azithromycin for the treatment of gonorrhea. However, there was no reported antagonism when rifampicin was combined with ceftriaxone or cefixime (6) Dual therapy is currently recommended by the CDC for the treatment of uncomplicated N. gonorrhoeae infections (3) and assessment of drug antagonism is important when new combinations are considered. Combining a macrolide with either an aminoglycoside or fluoroquinolone effectively inhibited growth with MIC values that were similar to single antibiotic usage. The combination appeared to be additive rather than synergistic. Since N. gonorrhoeae has developed and retained resistance to ciprofloxacin in the US (7), adding azithromycin in combination would likely be ineffective in treating isolates that are resistant to ciprofloxacin. However, there were no antagonistic outcomes on both antibiotics in assessing the in vitro growth of N. gonorrhoeae and this may be an important observation for using fluoroquinolones other than ciprofloxacin in combination with azirthromycin. A recently completed clinical trial demonstrated the 100% and 99.5% success in treating patients with uncomplicated gonorrhea infections receiving azithromycin with gentamicin or gemifloxacin, respectively (8). In vitro assessment with antibiotic combinations was not performed in that study but our data support the observed clinical utility of these antibiotic combinations. 5

6 Resistance to therapeutic agents continues to evolve in N. gonorrhoeae leaving scant antibiotic choices for the treatment of uncomplicated gonococcal infections. As these evolutionary bacterial trends continue, new antibiotics are needed. Until new antibiotics are developed, evaluated and approved for treatment, investigating existing antibiotics used in combination may be therapeutically relevant. 104 References Unemo M, Nicholas RA Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 7: Barry PM, Klausner JD The use of cephalosporins for gonorrhea: The impending problem of resistance. Expert Opin. Pharmacother. 10: Centers for Disease Control and Prevention Update to CDC's sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer recommended for treatment of gonococcal infections. MMWR. 61: Barbee LA, Soge OO, Holmes KK, Golden MR In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae. J. Antimicrob. Chemother. 69: Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project (GISP) Protocol pdf 6. Odds FC Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemotherap. 52:1. 7. Centers for Disease Control and Prevention. GISP Supplement and Profiles, Kirkcaldy RD, Weinstock HS, Moore PC, Philip SS, Wiesenfeld HC, Papp JR, Kerndt PR, Johnson S, Deal CD, Ghanem KG, Hook III EW The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin. Infect. Dis. 59:

7 124 Table 1. Minimum inhibitory concentration values when testing Neisseria gonorrhoeae with single and combination antibiotics. Minimum Inhibitory Concentration (µg/ml) 50% 90% 50% 90% 50% 90% Single Antibiotic Test AZI 1 GEN 2 AZI 1 GEN 2 AZI 1 CIP 3 AZI 1 CIP 3 AZI 1 RIF 4 AZI 1 RIF Dual Antibiotic Test AZI / GEN 5 AZI / GEN 5 AZI / CIP 6 AZI / CIP 6 AZI / RIF 7 AZI / RIF / 4 2 / / 4 4 / / 8 4 / Azithomycin 2 Gentamicin 3 Ciprofloxacin 4 Rifampicin 5 Combination of azithromycin and gentamicin 6 Combination of azithromycin and ciprofloxacin 7 Combination of azithromycin and rifampicin

8 Table 2. Minimum inhibitory concentration values (MIC) and Fractional Inhibitory Concentration Index (FICI) when testing Neisseria gonorrhoeae with the combination of gentamicin and azithromycin. MIC (µg/ml), median (range) Gentamicin plus Azithromycin n MIC GEN 1 MIC GEN (with AZI) 2 MIC AZI 3 MIC AZI (with GEN) 4 FICI 5 FICI Interpretation 6 Stratified by Gentamicin MIC Gentamicin MIC 1-2µg/ml 39 2 (1-2) 4 (0.5-4) 0.25 ( ) 0.25 ( ) 2.5 (1.5-3) Indifference Gentamicin MIC 4µg/ml 60 4 (4) 8 (2-8) 0.5 ( ) (0.06-8) 2.5 (2.1-3) Indifference Stratified by Azithromycin MIC Azithromycin MIC 0.25µg/ml 27 2 (1-4) 4 (0.5-8) 0.25 ( ) ( ) 2.5 (2-3) Indifference Azithromycin MIC 0.5-1µg/ml 55 4 (2-4) 8 (2-8) 0.5 (0.5-1) 0.25 (0.06-1) 2.5 (1.5-3) Indifference Azithromycin MIC 2-8µg/ml 17 4 (2-4) 8 (2-8) 8 (2-8) 2 (0.25-8) 2.25 (2.13-3) Indifference Overall Total 99 4 (1-4) 8 (0.5-8) 0.5 (0.16-8) 0.25 ( ) 2.5 (1.5-3) Indifference 1 Gentimicin MIC 2 MIC of gentamicin in combination with azithromycin 3 Azithromycin MIC 4 MIC of azithromycin in combination with gentamicin 5 Fractional inhibitory concentration index (FICI) 6 The FICI was interpreted as drug synergy (FICI 0.5), indifference (FICI > ), or drug antagonism (FICI >4.0)

9 Table 3. Minimum inhibitory concentration values (MIC) and Fractional Inhibitory Concentration Index (FICI) when testing Neisseria gonorrhoeae with the combination of ciprofloxacin and azithromycin. MIC (µg/ml), median (range) Rifampicin plus Azithromycin n MIC CIP MIC CIP (with AZI) MIC AZI MIC AZI (with CIP) FICI 1 FICI Interpretation Stratified by Ciprofloxacin MIC Ciprofloxacin MIC 0.25µg/ml ( ) ( ) 0.5 ( ) 0.25 ( ) 1.14 (0.34-3) Indifference Ciprofloxacin MIC 1-8µg/ml 21 4 (1-8) 2 (0.25-1) 0.5 (0.25-1) 0.25 ( ) 1 (0.75-2) Indifference Ciprofloxacin MIC 16-64µg/ml (16-64) 16 (8-32) 2 (0.5-8) 1.5 (0.25-8) 1.25 (0.38-2) Indifference Stratified by Azithromycin MIC Azithromycin MIC 0.25µg/ml (0.03-4) 0.03 ( ) 0.25 ( ) ( ) 1.5 (1.03-3) Indifference Azithromycin MIC 0.5-1µg/ml 44 2 ( ) 1 ( ) 0.5 (0.5-1) 0.38 ( ) 1.13 (0.34-2) Indifference Azithromycin MIC 2-8µg/ml (16-64) 16 (8-32) 4 (2-8) 2 (1-8) 1 (0.38-2) Indifference Overall Total 99 4 ( ) 4 ( ) 0.5 ( ) 0.5 (0.06-8) 1.03 (0.34-3) Indifference 1 Ciprofloxacin MIC 2 MIC of ciprofloxacin in combination with azithromycin 3 Azithromycin MIC 4 MIC of azithromycin in combination with ciprofloxacin 5 Fractional inhibitory concentration index (FICI) 6 The FICI was interpreted as drug synergy (FICI 0.5), indifference (FICI > ), or drug antagonism (FICI >4. 9

10 Table 4. Minimum inhibitory concentration values (MIC) and Fractional Inhibitory Concentration Index (FICI) when testing Neisseria gonorrhoeae with the combination of rifampicin and azithromycin. MIC (µg/ml), median (range) Rifampicin plus Azithromycin n MIC RIF MIC RIF (with AZI) MIC AZI MIC AZI (with RIF) FICI 1 FICI Interpretation Stratified by Rifampicin MIC Rifampicin MIC 0.06µg/ml ( ) ( ) 0.5 (0.03-8) 0.5 ( ) 3.08 ( ) Indifference Rifampicin MIC µg/ml ( ) 4 ( ) 0.5 (0.03-1) 0.5 ( ) 2.25 (1.12-9) Indifference Rifampicin MIC 8µg/ml 45 8 (8) 8 (8) 0.5 (0.06-8) 0.5 (0.03-8) 2 (1.06-5) Indifference Stratified by Azithromycin MIC Azithromycin MIC 0.25µg/ml ( ) 0.25 ( ) 0.25 ( ) 0.25 ( ) 3 ( ) Indifference Azithromycin MIC 0.5-1µg/ml 40 1 (0.03-8) 4.25 ( ) 0.5 (0.5-1) 0.5 (0.25-1) 2.58 ( ) Indifference Azithromycin MIC 2-8µg/ml 18 8 ( ) 8 (0.06-8) 8 (2-8) 8 (0.25-8) 2 ( ) Indifference Overall Total 99 8 ( ) 8 ( ) 0.5 (0.03-8) 0.5 ( ) 2.58 ( ) Indifference 1 Rifampicin MIC 2 MIC of rifampicin in combination with azithromycin 3 Azithromycin MIC 4 MIC of azithromycin in combination with rifampicin 5 Fractional inhibitory concentration index (FICI) 6 The FICI was interpreted as drug synergy (FICI 0.5), indifference (FICI > ), or drug antagonism (FICI >4.0) 10

The Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea

The Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea The Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea Robert D. Kirkcaldy, MD, MPH Division of STD Prevention National Center for HIV/AIDS, Viral Hepatitis, TB and STD Prevention Centers

More information

Neisseria gonorrhoeae: testing, typing and treatment in an era of increased antimicrobial resistance Wind, C.M.

Neisseria gonorrhoeae: testing, typing and treatment in an era of increased antimicrobial resistance Wind, C.M. UvA-DARE (Digital Academic Repository) Neisseria gonorrhoeae: testing, typing and treatment in an era of increased antimicrobial resistance Wind, C.M. Link to publication Citation for published version

More information

CDC Grand Rounds: The Growing Threat of Multidrug-

CDC Grand Rounds: The Growing Threat of Multidrug- Page 1 of 8 Morbidity and Mortality Weekly Report (MMWR) CDC Grand Rounds: The Growing Threat of Multidrug- Resistant Gonorrhea Weekly February 15, 2013 / 62(06);103-106 Although gonorrhea has afflicted

More information

6. Gonococcal antimicrobial susceptibility

6. Gonococcal antimicrobial susceptibility 6. Gonococcal antimicrobial susceptibility Key points Gonococcal AMR continues to increase worldwide and could lead to a pandemic of extensively drug-resistant (XDR) N. gonorrhoeae with serious public

More information

RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance

RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance Ina Park, MD, MS University of California San Francisco California Prevention Training Center DISCLOSURE No Relevant

More information

Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes

Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes Cécile Bébéar French National Center for bacterial STIs Bordeaux University

More information

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson CODA-CERVA Report on susceptibility of Salmonella serotypes in Belgium 2014. Vicky Jasson Veterinary and Agrochemical Research Centre 1 Introduction Salmonella is one of the most important bacterial zoonotic

More information

Sexually Transmitted Disease Surveillance 1998 Supplement

Sexually Transmitted Disease Surveillance 1998 Supplement Sexually Transmitted Disease Surveillance 1998 Supplement Division of STD Prevention November 1999 Gonococcal Isolate Surveillance Project (GISP) Annual Report - 1998 DEPARTMENT OF HEALTH AND HUMAN SERVICES

More information

Treatment resistant STIs relevant to MSM

Treatment resistant STIs relevant to MSM Treatment resistant STIs relevant to MSM David A. Lewis FRCP (UK) PhD Centre for HIV and STIs National Institute for Communicable Diseases (NHLS) Johannesburg, South Africa Regional Director, IUSTI Africa

More information

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

STD UPDATE Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018

STD UPDATE Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018 Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018 MISSION Improve health outcomes in communities disproportionately impacted by HIV and STDs Collect, study and publish data Diagnose and

More information

6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?

6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.? BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection

More information

Management of Gonorrhea in Adolescents and Adults in the United States

Management of Gonorrhea in Adolescents and Adults in the United States SUPPLEMENT ARTICLE Management of Gonorrhea in Adolescents and Adults in the United States Sarah Kidd 1 and Kimberly A. Workowski 1,2 1 Division of STD Prevention, Centers for Disease Control and Prevention,

More information

Neisseria gonorrhoeae azithromycin susceptibility in the United States, the Gonococcal Isolate Surveillance Project:

Neisseria gonorrhoeae azithromycin susceptibility in the United States, the Gonococcal Isolate Surveillance Project: AAC Accepts, published online ahead of print on 1 December 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04337-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Neisseria

More information

Gonorrhea Antimicrobial Resistance in Alberta. Gonorrhea Antimicrobial Resistance Review

Gonorrhea Antimicrobial Resistance in Alberta. Gonorrhea Antimicrobial Resistance Review 2011 Review in Alberta Alberta Gonorrhea AMR Surveillance Working Group November 2013 2011 Review Background Gonorrhea remains one of the oldest infections known to man. Infections can result in significant

More information

Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar

Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar French Na*onal Center for bacterial STIs Bordeaux University hospital, Bordeaux, France University of Bordeaux,

More information

Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae

Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae medicaldaily.com http://en.vircell.com/diseases ppcorn.com Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae Robert Nicholas University of North Carolina at Chapel Hill cdc.gov Timeline

More information

Validation of the MALDI-TOF for the Identification of Neisseria gonorrhoeae

Validation of the MALDI-TOF for the Identification of Neisseria gonorrhoeae Proposal Validation of the MALDI-TOF for the Identification of Neisseria gonorrhoeae Laboratory Director Sandip H. Shah, Ph.D. 517-335-8063 517-335-8051 (fax) ShahS@Michigan.gov Acting Director, Division

More information

Biological Consulting Services

Biological Consulting Services Biological Consulting Services of North Florida/ Inc. May 13, 2009 Aphex BioCleanse Systems, Inc. Dear Sirs, We have completed antimicrobial efficacy study on the supplied Multi-Purpose Solution. The testing

More information

Prevalence of and Associated Risk Factors for Fluoroquinolone-Resistant Neisseria gonorrhoeae in California,

Prevalence of and Associated Risk Factors for Fluoroquinolone-Resistant Neisseria gonorrhoeae in California, MAJOR ARTICLE Prevalence of and Associated Risk Factors for Fluoroquinolone-Resistant Neisseria gonorrhoeae in California, 2000 2003 Heidi M. Bauer, 1 Karen E. Mark, 4,8,a Michael Samuel, 1 Susan A. Wang,

More information

Determination of MIC & MBC

Determination of MIC & MBC 1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight

More information

Evaluation of Antibacterial Effect of Odor Eliminating Compounds

Evaluation of Antibacterial Effect of Odor Eliminating Compounds Evaluation of Antibacterial Effect of Odor Eliminating Compounds Yuan Zeng, Bingyu Li, Anwar Kalalah, Sang-Jin Suh, and S.S. Ditchkoff Summary Antibiotic activity of ten commercially available odor eliminating

More information

* these authors contributed equally to the preparation of this report

* these authors contributed equally to the preparation of this report AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in Neisseria gonorrhoeae, United States

Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in Neisseria gonorrhoeae, United States RESEARCH Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in Neisseria gonorrhoeae, United States Edward Goldstein, Robert D. Kirkcaldy, David Reshef,

More information

Zoliflodacin (ETX0914) for Uncomplicated Gonorrhoea

Zoliflodacin (ETX0914) for Uncomplicated Gonorrhoea Zoliflodacin (ETX0914) for Uncomplicated Gonorrhoea Global Antibiotic Research and Development Partnership, Pasteur Institute, 29 February, 2016 Entasis Therapeutics - Introduction Entasis Therapeutics

More information

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea Original Article Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea Stephanie N. Taylor, M.D., Jeanne Marrazzo, M.D., M.P.H., Byron E. Batteiger, M.D., Edward W. Hook, III, M.D.,

More information

Antimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand,

Antimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand, Antimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand, 2014-15 December 2015 PREPARED FOR: CLIENT REPORT No: PREPARED BY: Ministry of Health FW15061 Helen Heffernan,

More information

Strain Typing and Antimicrobial Resistance of Fluoroquinolone-Resistant Neisseria

Strain Typing and Antimicrobial Resistance of Fluoroquinolone-Resistant Neisseria JCM Accepts, published online ahead of print on 22 July 2009 J. Clin. Microbiol. doi:10.1128/jcm.01001-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Internationell utblick STI/HIV i världen

Internationell utblick STI/HIV i världen Internationell utblick STI/HIV i världen Magnus Unemo, PhD, Assoc. Professor, Director Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology Örebro University

More information

Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae

Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae International Journal of Antimicrobial Agents 31S (2008) S35 S39 Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae T. Matsumoto Department of Urology, School

More information

The Gonococcal Antimicrobial Surveillance Program (GASP): A snapshot from Southern Africa Dumisile Venessa Maseko

The Gonococcal Antimicrobial Surveillance Program (GASP): A snapshot from Southern Africa Dumisile Venessa Maseko The Gonococcal Antimicrobial Surveillance Program (GASP): A snapshot from Southern Africa Dumisile Venessa Maseko Centre for HIV and STIs Na9onal Ins9tute for Communicable Diseases, Na9onal Health Laboratory

More information

Hawaii State Laboratories Required Submission Information for APHL RFP: Validation of the MALDI-TOF for the identification of Neisseria gonorrhoeae

Hawaii State Laboratories Required Submission Information for APHL RFP: Validation of the MALDI-TOF for the identification of Neisseria gonorrhoeae Hawaii State Laboratories Required Submission Information for APHL RFP: Validation of the MALDI-TOF for the identification of Neisseria gonorrhoeae 1. Please describe the laboratory s current MALDI-TOF

More information

12/8/12. Overview. Optimizing STD Management in HIVinfected Individuals: What s new in 2012

12/8/12. Overview. Optimizing STD Management in HIVinfected Individuals: What s new in 2012 Optimizing STD Management in HIVinfected Individuals: What s new in 2012 Gail Bolan, M.D. Director, Division of STD Prevention National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers

More information

Reevaluation of bacteriocinogeny in Neisseria

Reevaluation of bacteriocinogeny in Neisseria J. clin. Path., 1975, 28, 274-278 Reevaluation of bacteriocinogeny in Neisseria gonorrhoeae' JOAN SKERMAN KNAPP, STANLEY FALKOW, AND KING K. HOLMES2 From the Departments of Medicine and Microbiology, University

More information

Dr Selena Singh. Guy s and St Thomas NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014

Dr Selena Singh. Guy s and St Thomas NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Selena Singh Guy s and St Thomas NHS Foundation Trust, London 1-4 April 2014, Arena and Convention Centre Liverpool Performance of ceftriaxone 500mgcontaining

More information

National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae

National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2011 Streptococcus and STI Unit Bacteriology and Enteric Diseases Program National Microbiology Laboratory

More information

Synergism of Fosfomycin-Ampicillin and Fosfomycin-

Synergism of Fosfomycin-Ampicillin and Fosfomycin- ANTIMICROBiAL AGENTS AND CHEMoTHERAPY, May 1978, p. 75-79 66-484/78/13-75$2./ Copyright 1978 American Society for Microbiology Vol. 13, No. 5 Printed in U.S.A. Synergism of Fosfomycin-Ampicillin and Fosfomycin-

More information

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation Stephanie N Taylor, Louisiana State University David H Morris, Desert AIDS Project

More information

Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham

Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology

More information

Update on Treatment Options for Gonococcal Infections

Update on Treatment Options for Gonococcal Infections Update on Treatment Options for Gonococcal Infections Jason W. Lancaster, 1,2, * Monica V. Mahoney, 3 Sana Mandal, 1 and Kenneth R. Lawrence, 4 1 School of Pharmacy, Northeastern University, Boston, Massachusetts;

More information

Neisseria gonorrhoeae: The Ontario perspective. Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015

Neisseria gonorrhoeae: The Ontario perspective. Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015 Neisseria gonorrhoeae: The Ontario perspective Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015 Objectives Participants will be able to: Describe preferred specimen collection for testing

More information

Rifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology

Rifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1980, p. 658-662 0066-4804/80/04-0658/05$02.00/0 Vol. 17, No. 14 Treatment of Experimental Staphylococcal Infections: Effect of Rifampin Alone and in Combination

More information

MAJOR ARTICLE. It recently has been shown that as many as 42% of endocervical swab samples obtained from female sex

MAJOR ARTICLE. It recently has been shown that as many as 42% of endocervical swab samples obtained from female sex MAJOR ARTICLE Treatment Failure with the Use of Ciprofloxacin for Gonorrhea Correlates with the Prevalence of Fluoroquinolone-Resistant Neisseria gonorrhoeae Strains in Bangladesh Motiur Rahman, 1 Ashraful

More information

Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018

Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018 Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018 Page 1 Contents 1 Introduction Page 3 2 Contact details Page 4 3 Opening hours Page 4 4 Services provided

More information

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE OBJECTIVES FOR PHARMACISTS GOAL

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE OBJECTIVES FOR PHARMACISTS GOAL DISCLOSURE PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES Dr. Feller does not have any actual or potential conflicts of interest to disclose and will not be discussing

More information

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE GOAL

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE GOAL PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES Jade Feller, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System November 13, 2018 DISCLOSURE

More information

Sinan B. Issa, Dept. of Microbiology, College of Medicine, Tikrit University

Sinan B. Issa, Dept. of Microbiology, College of Medicine, Tikrit University A study on Mycoplasma and Ureaplasma species and their association with gonorrhea in infertile Sinan B. Issa, Dept. of Microbiology, College of Medicine, Tikrit University Abstract Humans can be infected

More information

Monitoring Antimicrobial Susceptibility of Neisseria gonorrhoeae

Monitoring Antimicrobial Susceptibility of Neisseria gonorrhoeae J HEALTH POPUL NUTR Oct;28(5):443-449 ISSN 16-997 $ 5.+. INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH Monitoring Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolated from

More information

Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013

Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013 Veterinary and Agrochemical Research Centre Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013 1 Introduction Commensal E. coli are regarded as general

More information

The objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and

The objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and 1 Antimicrobial resistant gonorrhea is an emerging public health threat that needs to be addressed. Neisseria gonorrhoeae is able to develop resistance to antimicrobials quickly. Effective antibiotic stewardship

More information

EPIDEMILOGICAL ANALYSIS OF NEISSERIA GONORRHOEAE ISOLATES BY ANTIMICROBIAL SUSCEPTIBILITY TESTING, AUXOTYPING AND SEROTYPING.

EPIDEMILOGICAL ANALYSIS OF NEISSERIA GONORRHOEAE ISOLATES BY ANTIMICROBIAL SUSCEPTIBILITY TESTING, AUXOTYPING AND SEROTYPING. Indian July-September Journal of 2007 Medical Microbiology, (2007) 25 (3):225-9 Original Article 225 EPIDEMILOGICAL ANALYSIS OF NEISSERIA GONORRHOEAE ISOLATES BY ANTIMICROBIAL SUSCEPTIBILITY TESTING, AUXOTYPING

More information

Novel pena mutations identified in Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone isolated between 2000 and 2014 in Japan

Novel pena mutations identified in Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone isolated between 2000 and 2014 in Japan J Antimicrob Chemother 2016; 71: 2466 2470 doi:10.1093/jac/dkw161 Advance Access publication 13 May 2016 Novel pena mutations identified in Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone

More information

Jeffrey D. Klausner, Mari-Rose Aplasca, Virginia P. Mesola, Gail Bolan, W. L. Whittington, and King K. Holmes

Jeffrey D. Klausner, Mari-Rose Aplasca, Virginia P. Mesola, Gail Bolan, W. L. Whittington, and King K. Holmes 729 Correlates of Gonococcal Infection and of Antimicrobial-Resistant Neisseria gonorrhoeae among Female Sex Workers, Republic of the Philippines, 1996 1997 Jeffrey D. Klausner, Mari-Rose Aplasca, Virginia

More information

National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2014

National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2014 1 National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2012 National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2014

More information

Transmission from the Oropharynx to the Urethra among Men who have Sex with Men

Transmission from the Oropharynx to the Urethra among Men who have Sex with Men MAJOR ARTICLE Chlamydia trachomatis and Neisseria gonorrhoeae Transmission from the Oropharynx to the Urethra among Men who have Sex with Men Kyle T. Bernstein, 1 Sally C. Stephens, 1 Pennan M. Barry,

More information

Against Aerobic Gram-Negative Bacilli

Against Aerobic Gram-Negative Bacilli ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,

More information

Emergence, spread and characteristics of Neisseria

Emergence, spread and characteristics of Neisseria Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden Daniel Golparian, Bengt Hellmark,

More information

Increasing Incidence of High-Level Tetracycline- Resistant Neisseria gonorrhoeae due to Clonal Spread and Foreign Import

Increasing Incidence of High-Level Tetracycline- Resistant Neisseria gonorrhoeae due to Clonal Spread and Foreign Import Original Article Yonsei Med J 2016 Mar;57(2):350-357 pissn: 0513-5796 eissn: 1976-2437 Increasing Incidence of High-Level Tetracycline- Resistant Neisseria gonorrhoeae due to Clonal Spread and Foreign

More information

In vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates

In vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro

More information

Veterinary and Agrochemical Research Centre

Veterinary and Agrochemical Research Centre Veterinary and Agrochemical Research Centre Report on susceptibility of Salmonella serotypes in Belgium. P. Butaye Susceptibility of Salmonella strains was assessed by MIC determination using Sensititer

More information

Susceptibility of Pathogens Associated with Pelvic Inflammatory Disease to Antimicrobial Agents in Western U.P. India

Susceptibility of Pathogens Associated with Pelvic Inflammatory Disease to Antimicrobial Agents in Western U.P. India ISSN: 2319-7706 Volume 4 Number 7 (2015) pp. 192-198 http://www.ijcmas.com Original Research Article Susceptibility of Pathogens Associated with Pelvic Inflammatory Disease to Antimicrobial Agents in Western

More information

Roula M. Abdel-Massih Dept. of Biology, University of Balamand, Lebanon

Roula M. Abdel-Massih Dept. of Biology, University of Balamand, Lebanon http://skinnywithfiber.org Roula M. Abdel-Massih Dept. of Biology, University of Balamand, Lebanon Ilex paraguariensis Classification and characteristics Family Aquifoliaceae Found mainly in South America

More information

NIH Public Access Author Manuscript Future Microbiol. Author manuscript; available in PMC 2013 October 01.

NIH Public Access Author Manuscript Future Microbiol. Author manuscript; available in PMC 2013 October 01. NIH Public Access Author Manuscript Published in final edited form as: Future Microbiol. 2012 December ; 7(12): 1401 1422. doi:10.2217/fmb.12.117. Emergence of multidrug-resistant, extensively drug-resistant

More information

Sexually Transmitted Diseases. Summary of CDC Treatment Guidelines

Sexually Transmitted Diseases. Summary of CDC Treatment Guidelines DC 2015 Sexually Transmitted Diseases Summary of CDC Treatment Guidelines These summary guidelines reflect the June 2015 update to the 2010 CDC Guidelines for Treatment of Sexually Transmitted Diseases.

More information

Sexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2011

Sexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2011 Sexually Transmitted Infection surveillance in Northern Ireland 2012 An analysis of data for the calendar year 2011 Contents Page Summary points. 3 Surveillance arrangements and sources of data.. 4 1:

More information

Extragenital Chlamydia and Gonorrhea. Angel Stachnik, MPH Sr. Epidemiologist Office of Epidemiology and Disease Surveillance

Extragenital Chlamydia and Gonorrhea. Angel Stachnik, MPH Sr. Epidemiologist Office of Epidemiology and Disease Surveillance Extragenital Chlamydia and Gonorrhea Angel Stachnik, MPH Sr. Epidemiologist Office of Epidemiology and Disease Surveillance Rate of Chlamydia (CT) and Gonorrhea (GC), Clark County, 2012-2016 600 Rate per

More information

A study on antimicrobial sensitivity pattern in Neisseria gonorrhoeae in a tertiary care hospital

A study on antimicrobial sensitivity pattern in Neisseria gonorrhoeae in a tertiary care hospital International Journal of Research in Medical Sciences Shariff VNSA et al. Int J Res Med Sci. 2017 Sep;5(9):3960-3965 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20173962

More information

Predicted Resistance at CDC

Predicted Resistance at CDC National Center for Emerging and Zoonotic Infectious Diseases Predicted Resistance at CDC Ian Plumb, MBBS MSc Medical Epidemiologist, NARMS Team, EDEB, DFWED PulseNet & OutbreakNet Regional Meeting, East

More information

Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH

Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Division of Infectious Diseases University of Alabama at Birmingham School of Medicine Birmingham, Alabama Outline Syphilis in all its

More information

Incidence, epidemiology and evolution of reduced susceptibility to ciprofloxacin in Neisseria gonorrhoeae

Incidence, epidemiology and evolution of reduced susceptibility to ciprofloxacin in Neisseria gonorrhoeae ORIGINAL ARTICLE Incidence, epidemiology and evolution of reduced susceptibility to ciprofloxacin in Neisseria gonorrhoeae in Korea Clin Microbiol Infect 1998; 4: 627-633 Kyungwon Lee l, Yunsop Chong ',

More information

Nigerian Journal of Experimental and Applied Biology

Nigerian Journal of Experimental and Applied Biology Nig. J ExptI. Appl. BioI. Vol. 1, No. 1, pp. 1-5 (2000) Copyright 2000 Beth-Bekka Academic Publishers Ltd Printed in Nigeria. All rights of reproduction in any form reserved Nigerian Journal of Experimental

More information

Sexually Transmitted Infection Treatment and HIV Prevention

Sexually Transmitted Infection Treatment and HIV Prevention Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.

More information

Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni

Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni J. Lin & M. Ensminger Department of Animal Science, The University of Tennessee, Knoxville,

More information

Learning Objectives. STI Update. Case 1 6/1/2016

Learning Objectives. STI Update. Case 1 6/1/2016 Learning Objectives STI Update June 16 th, 2016 Madhu Choudhary, MD. FIDSA Assoc. Prof of Medicine Albany Medical College Review screening recommendations for STI in different patient populations Describe

More information

particularly to third-generation cephalosporins,

particularly to third-generation cephalosporins, Research article Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, to 5: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation

More information

Incidence and Treatment Outcomes of Pharyngeal. Infections in Men Who Have Sex with Men: A 13-Year Retrospective Cohort Study

Incidence and Treatment Outcomes of Pharyngeal. Infections in Men Who Have Sex with Men: A 13-Year Retrospective Cohort Study MAJOR ARTICLE Incidence and Treatment Outcomes of Pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis Infections in Men Who Have Sex with Men: A 13-Year Retrospective Cohort Study Kaede V. Ota,

More information

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC), This document is scheduled to be published in the Federal Register on 11/16/2017 and available online at https://federalregister.gov/d/2017-24804, and on FDsys.gov BILLING CODE: 4163-18-P DEPARTMENT OF

More information

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Therapy for Uncomplicated Gonorrhea in Women

Therapy for Uncomplicated Gonorrhea in Women Infectious Diseases in Obstetrics and Gynecology 5:370-375 (1997) (C) 1998 Wiley-Liss, Inc. Grepafloxacin Versus Cefixime as Single-Dose Therapy for Uncomplicated Gonorrhea in Women T.F. Mroczkowski,*

More information

Gonorrhea. Epidemiology in the United States. Epidemiology by Demographics. This is a PDF version of the following document:

Gonorrhea. Epidemiology in the United States. Epidemiology by Demographics. This is a PDF version of the following document: National STD Curriculum PDF created November 7, 2018, 3:02 am Gonorrhea This is a PDF version of the following document: Disease Type 1: Pathogen-Based Diseases Disease 6: Gonorrhea You can always find

More information

Experimental Endocarditis Caused by Streptococcus sanguis:

Experimental Endocarditis Caused by Streptococcus sanguis: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1981, p. 1-14 66-484/81/71-5$2./ Vol. 2, No. 1 Experimental Endocarditis Caused by Streptococcus sanguis: Single and Combined Antibiotic Therapy MARIA V. VICENTE,

More information

EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator

EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24

More information

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA

More information

Disclosure Information Julie Stoltey, MD MPH

Disclosure Information Julie Stoltey, MD MPH Courtesy CDC Public Health Image Library The New Yorker 2012 2016 Update on Testing, Treatment, and Gonorrhea Resistance Julie Stoltey, MD, MPH STD Control Branch-California Dept. of Public Health Assistant

More information

Update on Sexually Transmitted Infections among Persons Living with HIV

Update on Sexually Transmitted Infections among Persons Living with HIV Update on Sexually Transmitted Infections among Persons Living with HIV Stephen A. Berry, MD PhD Assistant Professor of Medicine Johns Hopkins University Division of Infectious Diseases Abbreviations and

More information

Chlamydia Trachomatis and Neisseria Gonorrhoeae. Khalil G. Ghanem, MD Johns Hopkins University

Chlamydia Trachomatis and Neisseria Gonorrhoeae. Khalil G. Ghanem, MD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

STI 2016: Where We Need to Go

STI 2016: Where We Need to Go STI 2016: Where We Need to Go Gail Bolan, M.D. Director, Division of STD Prevention National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and Prevention Sexually

More information

National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2012

National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2012 1 National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2012 National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2012

More information

2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing

2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing 2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing Joan M. Chow, MPH, DrPH Surveillance, Epidemiology, Assessment & Evaluation Section Sexually Transmitted Disease Control Branch Division

More information

Sexually Transmitted Diseases

Sexually Transmitted Diseases Sexually Transmitted Diseases Ina Park, MD, MS California Prevention Training Center University of California San Francisco Dept of Family and Community Medicine Disclosures/Disclaimers No disclosures

More information

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18

More information

Comparison of Two Laboratory Techniques for Detecting Mycoplasmas in Genital Specimens. Osama Mohammed Saed Abdul-Wahab, BSc, MSc, PhD*

Comparison of Two Laboratory Techniques for Detecting Mycoplasmas in Genital Specimens. Osama Mohammed Saed Abdul-Wahab, BSc, MSc, PhD* Bahrain Medical Bulletin, Vol. 32, No. 4, December 200 Comparison of Two Laboratory Techniques for Detecting Mycoplasmas in Genital Specimens Osama Mohammed Saed Abdul-Wahab, BSc, MSc, PhD* Objective:

More information

CHAPTER 8 ANTIBACTERIAL ACTIVITY OF THE CRUDE ETHANOLIC EXTRACT AND THE ISOLATED COMPOUNDS FROM THE STEM OF COSTUS IGNEUS

CHAPTER 8 ANTIBACTERIAL ACTIVITY OF THE CRUDE ETHANOLIC EXTRACT AND THE ISOLATED COMPOUNDS FROM THE STEM OF COSTUS IGNEUS CHAPTER 8 ANTIBACTERIAL ACTIVITY OF THE CRUDE ETHANOLIC EXTRACT AND THE ISOLATED COMPOUNDS FROM THE STEM OF COSTUS IGNEUS 8.1 INTRODUCTION Medicinal plants are the backbone of traditional medicine and

More information

BECAUSE OF NEISSERIA GONORrhoeae

BECAUSE OF NEISSERIA GONORrhoeae PRELIMINARY COMMUNICATION Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefixime in Toronto, Canada Vanessa G. Allen, MD, MPH Leo Mitterni Christine Seah, MLT Anuradha Rebbapragada, PhD

More information

Khalil G. Ghanem, MD, PhD Associate Professor of Medicine Johns Hopkins University School of Medicine. April 2, 2014

Khalil G. Ghanem, MD, PhD Associate Professor of Medicine Johns Hopkins University School of Medicine. April 2, 2014 Khalil G. Ghanem, MD, PhD Associate Professor of Medicine Johns Hopkins University School of Medicine April 2, 2014 E-mail your questions for the presenter to: maphtc@jhsph.edu DISCLOSURES OFF- LABEL USES

More information

Emerging Issues in STDs and Resistance

Emerging Issues in STDs and Resistance Emerging Issues in STDs and Resistance Toye H. Brewer, MD Asst. Professor of Clinical Medicine University of Miami School of Medicine Co-Director- Fogarty International Training Program Outline Syphilis-

More information

The Local Health Performance Incentive Program: Year 3. Office of Public Health Practice

The Local Health Performance Incentive Program: Year 3. Office of Public Health Practice The Local Health Performance Incentive Program: Year 3 Office of Public Health Practice Background & General Program Overview Christopher Davis, PhD Office of Public Health Practice 3 Background In 2012

More information

Medical Director, Community & Behavioral Health Clinics Department of Health and Human Services

Medical Director, Community & Behavioral Health Clinics Department of Health and Human Services Patrick F. Luedtke MD, MPH Senior Public Health Officer Medical Director, Community & Behavioral Health Clinics Department of Health and Human Services I have no relevant financial disclosures Review current

More information

An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus

An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus Asian Biomedicine Vol. 4 No. 1 February 2010; 141-145 Brief communication (Original) An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus

More information

Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: when, where, and how to use?

Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: when, where, and how to use? REVIEW C URRENT OPINION Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: when, where, and how to use? Nicola Low a and Magnus Unemo b Purpose of review Molecular methods

More information